Polycystic Ovary Syndrome
Conditions
Interventions
medication group:medication
bariatric surgery group:bariatric surgery
Sponsors
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Reproductive women over 18 years old; 2. BMI greater than 27.5 kg/m2; 3. Diagnosed with PCOS (according to The Rotterdam definition,a consensus workshop sponsored by ESHRE/ASRM in Rotterdam in 2003); 4. Able to understand and sign informed consent.;Inclusion criteria: 1. Reproductive women over 18 years old; 2. BMI greater than 27.5 kg/m2; 3. Diagnosed with PCOS (according to The Rotterdam definition,a consensus workshop sponsored by ESHRE/ASRM in Rotterdam in 2003); 4. Able to understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Women with hysterectomy; 2. Patients diagnosed with congenital adrenal hyperplasia, Cushing's syndrome, androgen secreting tumors within five years; 3. Pregnant or lactating mothers; 4. Thrombosis related history or risk factors:deep vein thrombosis,pulmonary embolism,myocardial infarction (angina), valvular heart disease,atrial fibrillation,cerebrovascular accident (TIA); 5. Abnormal liver function caused by viral hepatitisl; 6. A history of liver malignancy or adenoma, a history of genital or breast malignancies; 7. Severe or frequent migraine attacks; 8. Renal insufficiency; 9. Other cases that may affect the efficacy of the drug, or the drugs may compromise the health of the patients.;Exclusion criteria: 1. Women with hysterectomy; 2. Patients diagnosed with congenital adrenal hyperplasia, Cushing's syndrome, androgen secreting tumors within five years; 3. Pregnant or lactating mothers; 4. Thrombosis related history or risk factors:deep vein thrombosis,pulmonary embolism,myocardial infarction (angina), valvular heart disease,atrial fibrillation,cerebrovascular accident (TIA); 5. Abnormal liver function caused by viral hepatitisl; 6. A history of liver malignancy or adenoma, a history of genital or breast malignancies; 7. Severe or frequent migraine attacks; 8. Renal insufficiency; 9. Other cases that may affect the efficacy of the drug, or the drugs may compromise the health of the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ovulation;Menstrual cycle;Ovary structure;Sex hormone levels;body mass index;Waist/hip;blood pressure;serum glucose;glycosylated hemoglobin;serum insulin;serum C-peptide;;Ovulation;Menstrual cycle;Ovary structure;Sex hormone levels;body mass index;Waist/hip;blood pressure;serum glucose;glycosylated hemoglobin;serum insulin;serum C-peptide; | — |
Countries
China
Contacts
Public ContactYin jun;Yin jun ;
Shanghai Jiao Tong University Affiliated Sixth People's Hospital ;Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Outcome results
None listed